z-logo
open-access-imgOpen Access
HOME / ARCHIVES / VOL. 10 NO. 4 (2020): VOLUME 10 ISSUE 4 / Original Articles Expression of BRAF V600E in Tissue Samples of Colorectal Carcinoma and Its Correlation with Various Clinico-Pathological Parameters
Author(s) -
Hina Wasti,
Summayyah Shawana,
Beenish Hussain,
Santosh Kumar Sidhwani,
Rubbab Mir,
Hareem Fatima
Publication year - 2020
Publication title -
the journal of bahria university medical and dental college
Language(s) - English
Resource type - Journals
eISSN - 2617-9482
pISSN - 2220-7562
DOI - 10.51985/jbumdc2020057
Subject(s) - medicine , colorectal cancer , pathological , immunohistochemistry , v600e , pathology , oncology , cancer , biology , mutation , biochemistry , gene
Objective: To determine the expression of BRAF V600E in tissue samples of colorectal carcinoma and to correlate it with various clinico-pathological parameters. Study design and setting: Cross-sectional study was conducted at department of Pathology, Pakistan Navy Station Shifa hospital Karachi from 1st March 2016 to 28th February 2019 Methodology: Total of 51 cases of colorectal cancer were analyzed for immunohistochemical staining using BRAF antibodies on representative tissue blocks. Clinical and pathological records were retrieved for data collection. The results of immunohistochemical analysis were correlated with the recorded clinico-pathological parameters. Results: In this study 51 cases of colorectal cancer were analyzed for immune expression of BRAF V600E. The age of the patients ranged from 14 to 85 years with the mean age of 60.96 years. Among the 51 cases, 37(72.5%) cases were males and 14(27.4%) were females. 37(72.5%) were localized to left side colon and 14(27.4%) were found in the right colon. For BRAF V600E, positive expression was seen in 20(39.2%) cases, whereas 31(60.7%) cases showed negative expression of BRAFV600E. No significant association was seen between BRAF V600E expression and histological variants like age, gender, tumor location and glandular carcinomas. Conclusion: BRAF V600E immunosuppression was seen in 39.2% of colorectal carcinoma in this study. No significant association was seen in BRAF V600E expression and histological variants

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here